Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB
Open Access
- 20 April 2005
- journal article
- clinical trial
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 30 (9) , 1741-1750
- https://doi.org/10.1038/sj.npp.1300736
Abstract
(±)3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) is a widely used illicit drug that produces toxic effects on brain serotonin axons and axon terminals in animals. The results of clinical studies addressing MDMA's serotonin neurotoxic potential in humans have been inconclusive. In the present study, 23 abstinent MDMA users and 19 non-MDMA controls underwent quantitative positron emission tomography (PET) studies using [11C]McN5652 and [11C]DASB, first- and second-generation serotonin transporter (SERT) ligands previously validated in baboons for detecting MDMA-induced brain serotonin neurotoxicity. Global and regional distribution volumes (DVs) and two additional SERT-binding parameters (DVspec and DVR) were compared in the two subject populations using parametric statistical analyses. Data from PET studies revealed excellent correlations between the various binding parameters of [11C] McN5652 and [11C]DASB, both in individual brain regions and individual subjects. Global SERT reductions were found in MDMA users with both PET ligands, using all three of the above-mentioned SERT-binding parameters. Preplanned comparisons in 15 regions of interest demonstrated reductions in selected cortical and subcortical structures. Exploratory correlational analyses suggested that SERT measures recover with time, and that loss of the SERT is directly associated with MDMA use intensity. These quantitative PET data, obtained using validated first- and second-generation SERT PET ligands, provide strong evidence of reduced SERT density in some recreational MDMA users.Keywords
This publication has 37 references indexed in Scilit:
- A Voxel-Based PET Investigation of the Long-Term Effects of “Ecstasy” Consumption on Brain Serotonin TransportersAmerican Journal of Psychiatry, 2004
- The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)Pharmacological Reviews, 2003
- Specific memory deficits in ecstasy users? The results of a meta‐analysisHuman Psychopharmacology: Clinical and Experimental, 2003
- Cognitive Performance of MDMA-Treated Rhesus Monkeys, Sensitivity to Serotonergic ChallengeNeuropsychopharmacology, 2002
- Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [11C]DASB PET Imaging StudyAmerican Journal of Psychiatry, 2001
- Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamineSynapse, 2001
- (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical StudiesNeuropsychobiology, 2000
- Kinetic Analysis of [11C]McN5652: A Serotonin Transporter RadioligandJournal of Cerebral Blood Flow & Metabolism, 1999
- Synthesis and biodistribution of a new radiotracer for in vivo labeling of serotonin uptake sites by PET, cis-N,N-[11C]dimethyl-3-(2′,4′-dichlorophenyl)-indanamine (cis-[11C]DDPI)International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neuronsPharmacology Biochemistry and Behavior, 1988